Merck Compensates Docs For Gardasil For Adult Women When Insurers Do Not
This article was originally published in The Pink Sheet Daily
Replacement dose program reflects Merck’s strategy to increase use in women ages 19 to 26, who may exceed insurers’ age limit for the cervical cancer vaccine.
You may also be interested in...
FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.